Lanfan Medical "15th Five-Year Plan" Launches New Chapter: Integration to Fill Gaps Meets Industry Opportunities, Glove Business Welcomes Greatest Performance Elasticity

How does AI Blue Sail Medical enhance glove competitiveness through Thai investments?

Text / You Shang

Recently, Blue Sail Medical participated in investor research, where management thoroughly reviewed past development, explaining their strategic layout in two core sectors: health protection and cardiovascular health. Standing at a critical juncture at the start of the 2026 “14th Five-Year Plan,” they addressed key market concerns such as raw material supply, capacity upgrades, and asset integration, signaling a business bottoming out and high-quality growth.

Looking back over its development, Blue Sail Medical has successfully completed a crucial transition from transformation to restructuring over the past decade. During the 13th Five-Year Plan, the company focused on its glove business as the main support, steadily advancing transformation and upgrading, laying a foundation for diversified development. In the 14th Five-Year Plan, the company underwent business restructuring; its cardiovascular sector faced procurement shocks, and health protection encountered industry consolidation and trade policy challenges. Management continued to push forward and overcome difficulties, laying a solid foundation for the 2026 “14th Five-Year” start. Now, both health protection and cardiovascular sectors have entered profitability, forming a “dual-wheel” positive growth pattern.

Notably, in 2025, the company’s health protection division brought in Thai industry investors, integrating nitrile glove and thermal power assets, solidifying the glove business foundation. Specifically, Thai investors increased their stake in the joint venture Shandong Health Technology by $200 million. The company used these funds to acquire two nitrile glove manufacturing bases and supporting Hongda thermal power assets, successfully integrating nitrile glove operations with key energy assets. This deal significantly addressed energy shortages, enhanced cost competitiveness of nitrile gloves, and brought capital inflows to the listed company, optimizing its asset-liability structure. Additionally, it secured a rare new thermal power cogeneration license, allowing the company to supply electricity and heat externally for extra profit, creating new growth points. Hongda Thermal Power, as the only heat source in the industrial park, not only serves the company’s production but also supplies energy to nearby residents and industries, with broad future growth potential.

Currently, due to geopolitical risks, raw material prices for gloves are highly volatile, with some suppliers even halting quotations. This market situation has become a focus for investors. The company states that the current market is in a “buying spree” phase; leading manufacturers still actively secure resources, while smaller firms struggle to obtain affordable raw materials, facing survival pressures. Blue Sail Medical has two unique advantages in raw material security: first, its nitrile glove business benefits from shareholder empowerment, with its subsidiary Shandong Health Technology’s Thai investor HKG possessing over 200,000 tons of nitrile latex capacity, providing stable and reasonably priced supply even in extreme market conditions; second, its PVC glove business leverages supply chain synergy, with the company’s controlling shareholder’s chemical division being a national leader in plasticizers and resin, ensuring stable raw material supply and transportation cost advantages. The company also employs multi-channel procurement strategies, locking in raw material costs for the first half of 2026 through strategic purchasing, effectively avoiding single-source risks and strengthening supply chain resilience.

As raw material prices rise, questions about whether glove price increases will suppress downstream demand have emerged. The company responds that glove demand is largely essential, so price hikes have limited impact on demand. Moreover, their jointly developed high-end polyurethane gloves with Wanhua Chemical have received positive market feedback and repeat orders, demonstrating market acceptance of higher glove prices.

In terms of performance, the company’s net profit attributable to shareholders in 2025 was a loss mainly due to the health protection sector, affected by international trade policy changes, one-time tax adjustments, and asset impairments. However, the gross margin of this sector turned positive in the fourth quarter, with core business profitability substantially recovering. With the implementation of the “14th Five-Year” strategy, combined with industry price increase cycles, capacity integration benefits, and the dual-wheel growth pattern, Blue Sail Medical is expected to shift from losses in 2025 to significant profits in 2026, with strong performance resilience.

Looking ahead to 2026, Chairman Liu Wenjing detailed six core drivers for the glove business to support the “14th Five-Year” start. First, the global glove industry has entered a healthy growth cycle; second, industry concentration continues to rise, allowing the company to fully benefit from industry dividends; third, influenced by international geopolitical tensions, rising oil prices have driven up key raw materials like nitrile latex, DOTP, and PVC resins, entering a price increase cycle. Historical experience shows that terminal glove prices tend to rise faster than raw materials, boosting sector profits; fourth, the company has reasonably provisioned for impairments on some old assets in 2025, streamlining operations; fifth, Thai investors aid in asset integration, improving overall operational efficiency; finally, the company’s innovation capacity continues to grow, with high-potential products like polyurethane gloves gradually achieving mass production, further enriching the product portfolio.